These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
129. Neutralizing Antibody-Mediated Response and Risk of BK Virus-Associated Nephropathy. Solis M; Velay A; Porcher R; Domingo-Calap P; Soulier E; Joly M; Meddeb M; Kack-Kack W; Moulin B; Bahram S; Stoll-Keller F; Barth H; Caillard S; Fafi-Kremer S J Am Soc Nephrol; 2018 Jan; 29(1):326-334. PubMed ID: 29042457 [TBL] [Abstract][Full Text] [Related]
130. Epitope-associated and specificity-focused features of EV71-neutralizing antibody repertoires from plasmablasts of infected children. Arthur Huang KY; Chen MF; Huang YC; Shih SR; Chiu CH; Lin JJ; Wang JR; Tsao KC; Lin TY Nat Commun; 2017 Oct; 8(1):762. PubMed ID: 28970483 [TBL] [Abstract][Full Text] [Related]
131. A Sequence in the loop domain of hepatitis C virus E2 protein identified in silico as crucial for the selective binding to human CD81. Chang CC; Hsu HJ; Yen JH; Lo SY; Liou JW PLoS One; 2017; 12(5):e0177383. PubMed ID: 28481946 [TBL] [Abstract][Full Text] [Related]
132. Humanisation of a claudin-1-specific monoclonal antibody for clinical prevention and cure of HCV infection without escape. Colpitts CC; Tawar RG; Mailly L; Thumann C; Heydmann L; Durand SC; Xiao F; Robinet E; Pessaux P; Zeisel MB; Baumert TF Gut; 2018 Apr; 67(4):736-745. PubMed ID: 28360099 [TBL] [Abstract][Full Text] [Related]
133. Tracking HCV protease population diversity during transmission and susceptibility of founder populations to antiviral therapy. Khera T; Todt D; Vercauteren K; McClure CP; Verhoye L; Farhoudi A; Bhuju S; Geffers R; Baumert TF; Steinmann E; Meuleman P; Pietschmann T; Brown RJ Antiviral Res; 2017 Mar; 139():129-137. PubMed ID: 28062191 [TBL] [Abstract][Full Text] [Related]
134. Viral evasion and challenges of hepatitis C virus vaccine development. Pierce BG; Keck ZY; Foung SK Curr Opin Virol; 2016 Oct; 20():55-63. PubMed ID: 27657659 [TBL] [Abstract][Full Text] [Related]
135. Affinity maturation of a broadly neutralizing human monoclonal antibody that prevents acute hepatitis C virus infection in mice. Keck ZY; Wang Y; Lau P; Lund G; Rangarajan S; Fauvelle C; Liao GC; Holtsberg FW; Warfield KL; Aman MJ; Pierce BG; Fuerst TR; Bailey JR; Baumert TF; Mariuzza RA; Kneteman NM; Foung SK Hepatology; 2016 Dec; 64(6):1922-1933. PubMed ID: 27641232 [TBL] [Abstract][Full Text] [Related]
136. Broad neutralization of hepatitis C virus-resistant variants by Civacir hepatitis C immunoglobulin. Tawar RG; Heydmann L; Bach C; Schüttrumpf J; Chavan S; King BJ; McClure CP; Ball JK; Pessaux P; Habersetzer F; Bartenschlager R; Zeisel MB; Baumert TF Hepatology; 2016 Nov; 64(5):1495-1506. PubMed ID: 27531416 [TBL] [Abstract][Full Text] [Related]
137. Novel functional hepatitis C virus glycoprotein isolates identified using an optimized viral pseudotype entry assay. Urbanowicz RA; McClure CP; King B; Mason CP; Ball JK; Tarr AW J Gen Virol; 2016 Sep; 97(9):2265-2279. PubMed ID: 27384448 [TBL] [Abstract][Full Text] [Related]
138. New perspectives for preventing hepatitis C virus liver graft infection. Felmlee DJ; Coilly A; Chung RT; Samuel D; Baumert TF Lancet Infect Dis; 2016 Jun; 16(6):735-745. PubMed ID: 27301929 [TBL] [Abstract][Full Text] [Related]